These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9595515)

  • 21. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
    Aronson DL; Chang P; Kessler CM
    Circulation; 1992 May; 85(5):1706-12. PubMed ID: 1533349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
    Korninger C; Matsuo O; Suy R; Stassen JM; Collen D
    J Clin Invest; 1982 Mar; 69(3):573-80. PubMed ID: 7199539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Calcitonin gene-related peptide and thrombolysis].
    Ding WH
    Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Apr; 21(2):80-2, 122. PubMed ID: 8223167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions of endothelins and EDRF in bovine native endothelial cells: selective effects of endothelin-3.
    Warner TD; Schmidt HH; Murad F
    Am J Physiol; 1992 May; 262(5 Pt 2):H1600-5. PubMed ID: 1590465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet activation by fibrinolytic agents: a potential mechanism for resistance to thrombolysis and reocclusion after successful thrombolysis.
    Leopold JA; Loscalzo J
    Coron Artery Dis; 1995 Dec; 6(12):923-9. PubMed ID: 8723013
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of a novel marine natural product: pyrano indolone alkaloid fibrinolytic compound on thrombolysis and hemorrhagic activities in vitro and in vivo.
    Yan T; Wu W; Su T; Chen J; Zhu Q; Zhang C; Wang X; Bao B
    Arch Pharm Res; 2015 Aug; 38(8):1530-40. PubMed ID: 25475097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta.
    Boulanger CM; Lüscher TF
    Circ Res; 1991 Jun; 68(6):1768-72. PubMed ID: 1903680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
    Pehrsson S; Johansson K; Kjaer M; Elg M
    Thromb Haemost; 2010 Dec; 104(6):1242-9. PubMed ID: 20806126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
    Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O
    Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coagulation in vivo microcirculation and in vitro caused by endothelin-1.
    Halim A; Kanayama N; el Maradny E; Maehara K; Terao T
    Thromb Res; 1993 Nov; 72(3):203-9. PubMed ID: 8303659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation.
    More RS; Underwood MJ; Brack MJ; Pringle S; de Bono DP; Gershlick AH
    Cardiovasc Res; 1993 Dec; 27(12):2200-4. PubMed ID: 8313429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Vivo Anticoagulant and Thrombolytic Activities of a Fibrinolytic Serine Protease (Brevithrombolase) With the k-Carrageenan-Induced Rat Tail Thrombosis Model.
    Majumdar S; Chattopadhyay P; Mukherjee AK
    Clin Appl Thromb Hemost; 2016 Sep; 22(6):594-8. PubMed ID: 25657326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.